Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
29 hedge funds and large institutions have $14.9M invested in Trillium Therapeutics Inc. in 2016 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 13 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
9% less funds holding
Funds holding: 32 → 29 (-3)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
71% less capital invested
Capital invested by funds: $51.3M → $14.9M (-$36.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$996K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$552K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$253K |
| 4 |
PCM
Prelude Capital Management
New York
|
+$230K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$224K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.46M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$4.43M |
| 3 |
DM
Deerfield Management
New York
|
-$2.55M |
| 4 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$2.17M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.96M |
TRIL Hedge Fund Activity: Q4 2016 in Review
29 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q4 2016, worth a combined $14.9M — down 71% from $51.3M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of TRIL and 10 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 11 added.
The largest buyer was Sectoral Asset Management, opening a new position worth an estimated $996K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $5.46M sold.
- 29 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q4 2016, down from 32 in Q3 2016.
- Funds reported $14.9M of Trillium Therapeutics Inc. stock for Q4 2016, down 71% quarter-over-quarter.
- 10 funds opened new Trillium Therapeutics Inc. positions in Q4 2016 and 13 closed out, a net change of -3 holders.
- The largest Trillium Therapeutics Inc. buyer in Q4 2016 was Sectoral Asset Management, an estimated $996K added.
- The largest Trillium Therapeutics Inc. seller in Q4 2016 was Point72 Asset Management, an estimated $5.46M sold.
Based on aggregated 13F filings for Q4 2016.